The Latest Breaking News from Merck & Co

This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

New York attorney general calls for stronger safety warning on popular asthma drug Singulair due to concerns about potential side effects.

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.06%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.18%. Stock index futures this morning are moderately higher. An increase in M&A activity supports stocks after Boston Scientific agreed to buy Axionics for $3.7 billion and Johnson...

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. Stocks on Thursday settled mixed, with the S&P...

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.13%. Stocks this morning are mixed, with the Nasdaq 100...

The Federal Reserve’s interest rate hikes since last year showed results as annual inflation dropped for the ninth consecutive month in March. However, with the Fed likely to hike the interest rate at the policy meeting next month, the risk of a recession looms. In this scenario, it could be…

Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of COVID treatments in the country that’s now facing a massive infection surge.